NorthStar Medical Radioisotopes, LLC

northstarnm.com

NorthStar Medical
At NorthStar Medical Radioisotopes, our mission is to provide patients global access to game-changing radiopharmaceuticals. We are a growing,

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

TONIX PHARMACEUTICALS COMPLETES CLINICAL PHASE OF PREVAIL PROOF-OF-CONCEPT STUDY OF TNX-102 SL FOR THE TREATMENT OF FIBROMYALGIA-TYPE LONG COVID

Globenewswire | August 14, 2023

news image

Tonix Pharmaceuticals Holding Corp. a biopharmaceutical company, today announced the completion of the clinical phase of the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL as a potential treatment for fibromyalgia-type Long COVID. Topline results for the PREVAIL study are expected in the third quarter of 2023. “Approximately 40% of U.S. Long COVID patients have fibromyalgia-like multi-site pain symptoms based on our observational studies of Long COVID patients from t...

Read More

RESEARCH

DOTLAB ANNOUNCES TOP-TIER, GLOBAL PHARMACEUTICAL RESEARCH CLIENTS FOR ITS DOTENDO PLATFORM

PR Newswire | January 09, 2024

news image

DotLab, a medical diagnostics company, announced top-tier pharmaceutical research clients for its DotEndo platform. The customers include global companies with interests in diagnosing or monitoring endometriosis on a Research Use Only basis in clinical trial subjects to support the development of new medicines. "We're proud to share the news of our global pharmaceutical partners, which are complementary to our planned, large clinical offering for commercial endometriosi...

Read More

Pharma Tech

EYENOVIA ANNOUNCES $15 MILLION CREDIT FACILITY WITH AVENUE VENTURE DEBT FUND

Eyenovia, Inc. | November 30, 2022

news image

Eyenovia, Inc. a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced that the company has entered into a $15 million credit facility with the Avenue Venture Opportunities Fund, L.P. The financing is intended to support manufacturing in anticipation of a MydCombi laun...

Read More

Business Insights

COLUBRISMX, INC. ANNOUNCES CORPORATE REBRANDING TO ENDOQUEST ROBOTICS™

ColubrisMX | July 01, 2022

news image

ColubrisMX, Inc., developer of the world's first flexible endoluminal robotic system which enables scar-free and less invasive surgical procedures, announced that the Company has rebranded to ENDOQUEST Robotics™. The Company also announced the simultaneous launch of its new website, www.endoquestrobotics.com. "Since being founded, our company has made rapid progress in the development of technologies that represent historic advances in endolumi...

Read More
news image

Pharmacy Market

TONIX PHARMACEUTICALS COMPLETES CLINICAL PHASE OF PREVAIL PROOF-OF-CONCEPT STUDY OF TNX-102 SL FOR THE TREATMENT OF FIBROMYALGIA-TYPE LONG COVID

Globenewswire | August 14, 2023

Tonix Pharmaceuticals Holding Corp. a biopharmaceutical company, today announced the completion of the clinical phase of the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL as a potential treatment for fibromyalgia-type Long COVID. Topline results for the PREVAIL study are expected in the third quarter of 2023. “Approximately 40% of U.S. Long COVID patients have fibromyalgia-like multi-site pain symptoms based on our observational studies of Long COVID patients from t...

Read More
news image

RESEARCH

DOTLAB ANNOUNCES TOP-TIER, GLOBAL PHARMACEUTICAL RESEARCH CLIENTS FOR ITS DOTENDO PLATFORM

PR Newswire | January 09, 2024

DotLab, a medical diagnostics company, announced top-tier pharmaceutical research clients for its DotEndo platform. The customers include global companies with interests in diagnosing or monitoring endometriosis on a Research Use Only basis in clinical trial subjects to support the development of new medicines. "We're proud to share the news of our global pharmaceutical partners, which are complementary to our planned, large clinical offering for commercial endometriosi...

Read More
news image

Pharma Tech

EYENOVIA ANNOUNCES $15 MILLION CREDIT FACILITY WITH AVENUE VENTURE DEBT FUND

Eyenovia, Inc. | November 30, 2022

Eyenovia, Inc. a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced that the company has entered into a $15 million credit facility with the Avenue Venture Opportunities Fund, L.P. The financing is intended to support manufacturing in anticipation of a MydCombi laun...

Read More
news image

Business Insights

COLUBRISMX, INC. ANNOUNCES CORPORATE REBRANDING TO ENDOQUEST ROBOTICS™

ColubrisMX | July 01, 2022

ColubrisMX, Inc., developer of the world's first flexible endoluminal robotic system which enables scar-free and less invasive surgical procedures, announced that the Company has rebranded to ENDOQUEST Robotics™. The Company also announced the simultaneous launch of its new website, www.endoquestrobotics.com. "Since being founded, our company has made rapid progress in the development of technologies that represent historic advances in endolumi...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us